MBS 2320

Drug Profile

MBS 2320

Alternative Names: MBS-2320

Latest Information Update: 04 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Aberdeen
  • Developer Modern Biosciences
  • Class Anti-inflammatories; Antirheumatics
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis

Most Recent Events

  • 30 May 2017 Phase-II clinical trials in Rheumatoid arthritis (Adjunctive treatment) in Georgia (PO), Rheumatoid arthritis (Adjunctive treatment) in Moldova (PO) (NCT03139136)
  • 02 May 2017 Modern Biosciences plans a phase IIa trial for Rheumatoid arthritis (Adjunctive treatment) (NCT03139136)
  • 01 Mar 2017 Modern Biosciences completes a phase I trial in Rheumatoid arthritis (Adjunctive treatment) in United Kingdom (NCT02480946)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top